Drugs & Aging

, Volume 7, Issue 1, pp 30–37 | Cite as

Rheumatoid Arthritis in the Elderly

Prevalence and Optimal Management
  • Dirkjan van Schaardenburg
Review Article Epidemiology

Summary

Elderly-onset rheumatoid arthritis (EORA), defined as rheumatoid arthritis (RA) with onset at age 60 years or over, differs slightly from younger-onset RA by a more equal gender distribution, a higher frequency of acute systemic onset with involvement of the shoulder, a higher disease activity, and, in later stages, more radiographic damage and functional decline. Several subsets of EORA are recognised, such as rheumatoid factor-positive RA, polymyalgia rheumatica and ‘remitting seronegative symmetrical synovitis with pitting oedema’. These conditions can be difficult to distinguish from crystal-induced arthritis, osteoarthritis and paraneoplastic arthritis. The efficacy and tolerability of second-line drugs is similar in both age groups, but in the elderly caution is needed with the use of nonsteroidal anti-inflammatory drugs and prednisone.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schnell A. The clinical features of rheumatic infection in the old. Acta Med Scand 1941; 106: 345–50CrossRefGoogle Scholar
  2. 2.
    Dordick JR. Rheumatoid arthritis in the elderly. J Am Geriatr Soc 1956; 4: 588–91PubMedGoogle Scholar
  3. 3.
    Ehrlich GE, Katz WA, Cohen SA. Rheumatoid arthritis in the aged. Geriatrics 1970; 25: 103–13PubMedGoogle Scholar
  4. 4.
    Corrigan AB, Robinson RG, Terenty TR, et al. Benign rheumatoid arthritis of the aged. BMJ 1974; 1: 444–6PubMedCrossRefGoogle Scholar
  5. 5.
    Terkeltaub R, Esdaile J, Décary F, et al. A clinical study of older age rheumatoid arthritis with comparison to a younger onset group. J Rheumatol 1983; 10: 418–24PubMedGoogle Scholar
  6. 6.
    Ferraccioli GF, Cavalieri F, Mercandati M, et al. Clinical features, scintiscan characteristics and X-ray progression of late onset rheumatoid arthritis. Clin Exp Rheumatol 1984; 2: 157–61PubMedGoogle Scholar
  7. 7.
    Deal CL, Meenan RF, Goldenberg DL, et al. The clinical features of elderly-onset rheumatoid arthritis. Arthritis Rheum 1985; 28: 987–94PubMedCrossRefGoogle Scholar
  8. 8.
    Symmons DPM, Barrett EM, Bankhead C, et al. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994; 33: 735–9PubMedCrossRefGoogle Scholar
  9. 9.
    van Schaardenburg D, Lagaay AM, Breedveld FC, et al. Rheumatoid arthritis in a population of persons aged 85 years and over. Br J Rheumatol 1993; 32: 104–9PubMedCrossRefGoogle Scholar
  10. 10.
    Mikkelsen WM, Dodge HJ, Duff IF, et al. Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959–60. J Chron Dis 1967; 20: 351–69PubMedCrossRefGoogle Scholar
  11. 11.
    Engel A, Roberts J, Burch TA. Rheumatoid arthritis in adults: United States 1960–1962. Public Health Service Publication no. 1000, series 11 — no. 17Google Scholar
  12. 12.
    Bergström G, Bjelle A, Sundh V, et al. Joint diseases at ages 70, 75 and 79 years — a cross-sectional comparison. Br J Rheumatol 1986; 25: 333–41PubMedCrossRefGoogle Scholar
  13. 13.
    Lawrence JS. Prevalence of rheumatoid arthritis. Ann Rheum Dis 1961; 20: 11–6PubMedCrossRefGoogle Scholar
  14. 14.
    Ward RH, Hasstedt SJ, Clegg DO. Population prevalence of rheumatoid arthritis is lower than formerly supposed [abstract]. Arthritis Rheum 1992; 35: S126Google Scholar
  15. 15.
    Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. J Rheumatol 1984; 11: 158–61PubMedGoogle Scholar
  16. 16.
    Inoue K, Shichikawa K, Nishioka J, et al. Older age onset rheumatoid arthritis with or without osteoarthritis. Ann Rheum Dis 1987; 46: 908–11PubMedCrossRefGoogle Scholar
  17. 17.
    Healey LA, Sheets PK. The relation of polymyalgia rheumatica to rheumatoid arthritis. J Rheumatol 1988; 15: 750–2PubMedGoogle Scholar
  18. 18.
    Van der Heijde DM, van Riel PL, van Leeuwen MA, et al. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective follow-up study of early rheumatoid arthritis. J Rheumatol 1991; 18: 1285–9PubMedGoogle Scholar
  19. 19.
    van Schaardenburg D, Hazes JMW, de Boer A, et al. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol 1993; 20: 45–52PubMedGoogle Scholar
  20. 20.
    Hazes JMW, Dijkmans BAC, Hoevers JM, et al. DR4 prevalence related to the age at disease onset in female patients with rheumatoid arthritis. Ann Rheum Dis 1989; 48: 406–8PubMedCrossRefGoogle Scholar
  21. 21.
    Fleming A, Crown JM, Corbett M. Prognostic value of early features in rheumatoid disease. BMJ 1976; 1: 1243–5PubMedCrossRefGoogle Scholar
  22. 22.
    Scott DL, Symmons DPM, Coulton BL, et al. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987; 1: 1108–11PubMedCrossRefGoogle Scholar
  23. 23.
    van Schaardenburg D, Lagaay AM, Otten HG, et al. The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 1993; 32: 546–9PubMedCrossRefGoogle Scholar
  24. 24.
    Salvarani C, Macchioni P, Mantovani W, et al. Polymyalgia rheumatica and seronegative rheumatoid arthritis: some observations based on a Northern Italian population. J Rheumatol 1993; 20: 756–7PubMedGoogle Scholar
  25. 25.
    Healey LA. Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity. J Rheumatol 1992; 19: 270–2PubMedGoogle Scholar
  26. 26.
    Martin BA, Morris JH. Polymyalgia rheumatica: an arthroscopic study of the shoulder joint. Ann Rheum Dis 1983; 42: 311–31PubMedCrossRefGoogle Scholar
  27. 27.
    McCarty DJ, O’Duffy JD, Pearson L, et al. Remitting seronegative symmetrical synovitis with pitting edema, RS3PE syndrome. JAMA 1985; 254: 2763–7PubMedCrossRefGoogle Scholar
  28. 28.
    Russell EB, Hunter JB, Pearson L, et al. Remitting, seronegative, symmetrical synovitis with pitting edema — 13 additional cases. J Rheumatol 1990: 17: 633–9PubMedGoogle Scholar
  29. 29.
    Puig JG, Michán AD, Jiménez ML, et al. Female gout: clinical spectrum and uric acid metabolism. Arch Intern Med 1991; 151: 726–32PubMedCrossRefGoogle Scholar
  30. 30.
    Gonzalez EB, Miller SB, Agudelo CA. Optimal management of gout in older patients. Drugs Aging 1994; 4: 128–34PubMedCrossRefGoogle Scholar
  31. 31.
    Jones AC, Chuck AJ, Arie EA, et al. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 1992; 22: 188–202PubMedCrossRefGoogle Scholar
  32. 32.
    McCarty DJ. Diagnostic mimicry in arthritis — patterns of joint involvement associated with calcium pyrophosphate dihydrate crystal deposits. Bull Rheum Dis 1975; 25: 804–9Google Scholar
  33. 33.
    Beihorn LR, Hess EV. Erosive osteoarthritis. Semin Arthritis Rheum 1993; 22: 298–306CrossRefGoogle Scholar
  34. 34.
    Sheon RP, Kirsner AB, Tangsintanapas P, et al. Malignancy in rheumatic disease: interrelationships. J Am Geriatr Soc 1977; 25: 20–7PubMedGoogle Scholar
  35. 35.
    Mackenzie AH, Scherbel AL. Connective tissue syndromes associated with carcinoma. Geriatrics 1963; 18: 745–53PubMedGoogle Scholar
  36. 36.
    O’Callaghan JW, Brooks PM. Disease-modifying agents and immunosuppressive drugs in the elderly. Clin Rheum Dis 1986; 12: 275–89PubMedGoogle Scholar
  37. 37.
    Singh G, Ramey DR, Fries JF. Effectiveness and toxicity profiles of drug treatment in RA [abstract]. Arthritis Rheum 1994; 37: S196CrossRefGoogle Scholar
  38. 38.
    Fries JF, Williams CA, Morfeld D, et al. Reduction in long-term disability in rheumatoid arthritis by DMARD-based strategies. Arthritis Rheum 1994; 37: S420Google Scholar
  39. 39.
    Blackshear JL, Napier JS, Davidman M, et al. Renal complications of nonsteroidal antiinflammatory drugs: identification and monitoring of those at risk. Semin Arthritis Rheum 1985; 14: 163–75PubMedCrossRefGoogle Scholar
  40. 40.
    Schlegel SI, Paulus HE. Non-steroidal and analgesic therapy in the elderly. Clin Rheum Dis 1986; 12: 245–73PubMedGoogle Scholar
  41. 41.
    Matthewson K, Pugh S, Northfield TC. Which peptic ulcer patients bleed? Gut 1988; 29: 70–4PubMedCrossRefGoogle Scholar
  42. 42.
    Pincus T, Marcum SB, Callahan LF, et al. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs. J Rheumatol 1992; 19: 1874–84PubMedGoogle Scholar
  43. 43.
    Langman MJS, Weil J, Wainwright P, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal antiinflammatory drugs. Lancet 1994; 343: 1075–8PubMedCrossRefGoogle Scholar
  44. 44.
    Garcia LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs. Lancet 1994; 343: 769–72CrossRefGoogle Scholar
  45. 45.
    Myles A. Corticosteroid treatment in rheumatoid arthritis. Br J Rheumatol 1985; 24: 125–7PubMedCrossRefGoogle Scholar
  46. 46.
    Pincus T, Marcum SB, Callahan LF, et al. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885–94PubMedGoogle Scholar
  47. 47.
    Lockie LM, Gomez E, Smith DM. Low dose adrenocorticosteroids in the management of elderly patients with rheumatoid arthritis. Semin Arthritis Rheum 1983; 12: 373–81PubMedCrossRefGoogle Scholar
  48. 48.
    Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991; 18: 804–8PubMedGoogle Scholar
  49. 49.
    van Schaardenburg D, Valkema R, Dijkmans BAC, et al. Prednisone for elderly-onset rheumatoid arthritis: outcome and bone mass in comparison to treatment with chloroquine. Arthritis Rheum 1995; 38: 334–42PubMedCrossRefGoogle Scholar
  50. 50.
    Dahl SL, Samuelson CO, Williams J, et al. Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three comtrolled trials. Pharmacotherapy 1990; 10: 79–84PubMedGoogle Scholar
  51. 51.
    Capell HA, Porter DR, Madhok R, et al. Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? Ann Rheum Dis 1993; 52: 423–8PubMedCrossRefGoogle Scholar
  52. 52.
    Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994–1002PubMedGoogle Scholar
  53. 53.
    Wijnands MJH, van Riel PLCM, Gribnau FWJ, et al. Risk factors of second-line antirheumatic drugs in rheumatoid arthritis. Semin Arthritis Rheum 1990; 19: 337–52PubMedCrossRefGoogle Scholar
  54. 54.
    Walker AM, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993; 36: 329–35PubMedCrossRefGoogle Scholar
  55. 55.
    Larsson L, Grimby G, Karlsson J. Muscle strength and speed of movement in relation to age and muscle morphology. J Appl Physiol 1979; 46: 451–6PubMedGoogle Scholar
  56. 56.
    Fiatarone MA, O’Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330: 1769–75PubMedCrossRefGoogle Scholar
  57. 57.
    Hosick WB, Baldurin AE. Total knee arthroplasty in patients over 80 years [abstract]. Arthritis Rheum 1992; 35: S90Google Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Dirkjan van Schaardenburg
    • 1
  1. 1.Rheumatology ClinicJan van Breemen Institute, Centre for Rheumatology and RehabilitationAmsterdamThe Netherlands

Personalised recommendations